October 2025: JWCA advises Karyopharm Therapeutics on its $170.3 million restructuring transaction including a term loan and convertible issuance, convertible equitization, and convertible exchange
May 2024: JWCA advises Karyopharm Therapeutics on its $100 million term loan, $116 million secured convertible exchange, and royalty restructuring
October 2018: JWCA advises Karyopharm Therapeutics on its $173 million convertible debt offering
